August 11, 2020 8:07am

 

Earnings’ results invite questionable judgment calls

Pre-open indications: 3 BUYs and 6 SELLs

What I provide is an intelligence daily. RMi outlines the potential prelude to the daily dosage of facts and objectivity! Subscription is coming, it’s not conscription but, an offer to join our collective of like-minded investors!

My gift to you, I've kept RMi subscription FREE during these COVID-19 and volatile times!

Dow futures are UP +0.96% (+266 points), S&P futures are UP +0.57% (+19 points) and NASDAQ futures are UP +0.19% (+22 points)

 

Futures advanced in early morning trading Tuesday after yesterday’s gains elevated the S&P 500 within striking distance of a record high;

European markets rally on recovery hopes as the pan-European Stoxx 600 climbed 1.9% by mid-morning;

Asia Pacific markets mostly rose as headline risks dominate amid lingering US fiscal uncertainties and rising US-China tension.

 

Henry’omics:

The morning’s upside move comes shortly after local news agencies reported Russian President Putin claimed the country had given regulatory approval for the world’s first Covid-19 vaccine.

While there was skepticism about whether Russia had developed a safe vaccine so quickly, the news triggered optimism from investors about the race for an inoculation and perhaps that the market isn’t pricing in how quickly a valid one could be ready. <CNBC>

 

Monday night’s post title – “one can never be too liquid”

  • The NASDAQ closed DOWN -42.63 points (-0.39%);
  • the IBB closed down -1% and XBI also closed down -0.01%;
  • Sector volume was LOW with 3 of the 25-upside having higher than the 3-month average volume and the 2 of 8-downside having higher than the 3-month average volume;
  • The CBOE Volatility Index (VVIX: INDEX) was down -0.08 points or -0.35% at 22.13;
  • Monday’s percentage (%) of the 25-upside were +0.06% (CLLS) to +8.60% (MESO) while the 8-downside ranges from -$0.09 (VYGR) to -4.50% (GBT); 

 

Last five (5) sessions:

  • Monday (8/10) closed positive with 25 advancers, 8 declines and 2 flats
  • Friday closed positive with 21 advancers, 11 decline and 3 flats
  • Thursday closed negative with 11 advancers, 23 decline and 1 flat
  • Wednesday closed positive with 19 advancers, 15 decline and 1 flat
  • Last Tuesday closed negative with 13 advancers, 20 decline and 2 flats

 

Q3 so far:

  • August, 4 positive closes and 2 negative closes
  • July -11 positive and 11 negative closes with 1 holiday

 

Companies in my headlights – It’s your decision; I provide an idea and context:

Maintaining Sell:

Biostage (BSTG) closed up +$0.19 after Friday’s +$0.20, Thursday’s +$0.32 to $2.50, Wednesday’s +$2.18 and last Tuesday’s -$2.12.  Keep writing those checks to “PUMP” the share price.

Remember, there are millions of private placement millions unregistered shares (priced at $3.20, $3.60 and $3.70) existing FAR beyond the outstanding shares with more coming …

Mrs. bin Zhao, the major stock holder and head of DST Capital, BSTG’s funder: if you had stuck to the original turn-around plan, BSTG would NOT be in this position! YOU will also be held RESPONSIBLE IF and WHEN the Feds step-in.

  • Facts are irrefutable and the First amendment of the U.S. Constitution protects American’s free speech.

BUY:

Pluristem (PSTI) closed up +$0.03 after Friday’s -$0.13 to $8.97 and has a positive +$0.19 or +2.11% positive pre-market indication after PSTI receives clearance to begin P2 trials in Germany. Germany’s health regulatory agency, the Paul Ehrlich Institute (PEI), has cleared the P2 clinical protocol for its study titled, “A Randomized, Controlled, Multicenter, Parallel-Group Phase II Study to Evaluate the Efficacy and Safety of Intramuscular Injections of PLX PAD for the Treatment of severe COVID-19.” Forty (40) patients hospitalized with severe cases of COVID-19 complicated by Acute Respiratory Distress Syndrome (ARDS) will be enrolled in the study.

After earnings announcements:

SELL:

Athersys (ATHX) closed down -$0.03 to $2.59 and has a negative -$0.19 or -7.34% aftermarket indication;

bluebird bio (BLUE) closed up +$2.29 to $65.77 and has a negative -$1.12 or -1.70% aftermarket indication;

Mesoblast (MESO) closed up +1.38 to $17.42 and has a negative -$3.22 or -18.48% aftermarket indication;

Precigen (PGEN) closed up +$0.24 to $5.12 and has a negative -$$0.12 or -2.34 aftermarket indication;

BUY:

Adverum Biotechnologies (ADVM) closed up +$0.24 to $18.70 and has appositive +$0.80 or +4.28% aftermarket indication;

Global Blood Therapeutics (GBT) closed down -$2.87 and has a positive +$0.55 or +0.90% aftermarket indication;

Sell Into strength:

BioLife Solutions (BLFS) closed up +$1.55 to $22.57 and has a positive +$0.68 or +3.01% aftermarket indication;

 

The BOTTOM LINE: I’m on vacation but, still watching!

Investors are questioning the fate of further coronavirus talks re stimulus aimed at supporting Americans during the pandemic.

And, the sector is what it is, until it isn’t and even then, it doesn’t seem to be…

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.